Drug intelligence / Profile preview

ACU-D2

Development stage: Preclinical
Lead developer: Accuitis
Modality: Small Molecules

Overview

ACU-D2 is a small molecule drug developed by Accuitis, Inc. It acts as a SIRT3 agonist, targeting the NAD-dependent protein deacetylase sirtuin-3, which is primarily located in mitochondria. ACU-D2 is being investigated for its therapeutic potential in treating systemic scleroderma.

Targets

SIRT3 (NAD-dependent protein deacetylase sirtuin-3)

Beyond the preview

Go deeper on ACU-D2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACU-D2.

Explore the full profile